文献速递关节外科

唐氏综合征患者初次全髋关节置换术后10年假体生存率优异:一项回顾性队列研究

Excellent 10-Year Implant Survivorship Following Primary Total Hip Arthroplasty in Patients Who Have Down Syndrome: A Retrospective Cohort Study.
PubMed 文献 · J Arthroplasty · 2026-10-14

本研究基于大型国家数据库回顾性分析255例唐氏综合征(21三体)患者初次全髋关节置换术(THA)后10年结局,Kaplan-Meier分析显示无翻修生存率94.6%、无机械失败生存率85.9%、无后续髋或骨盆手术生存率72.6%。倾向性评分匹配分析(每组246例)显示,唐氏综合征与非唐氏综合征患者在翻修THA、机械失败及后续髋或骨盆手术率上均无统计学显著差异。结论认为21三体本身不损害10年假体耐久性,支持THA作为经适当选择患者的持久治疗选择。

要点

  • 唐氏综合征患者初次THA后10年无翻修生存率为94.6%。
  • 匹配分析显示唐氏综合征与非唐氏综合征患者10年机械结局无显著差异。
  • 21三体本身不损害THA假体10年耐久性。

核心结论

  • 唐氏综合征患者初次THA后10年假体生存率优异,与匹配对照相当。
  • 21三体本身不损害10年假体耐久性,支持THA作为经适当选择患者的持久治疗选择。

研究设计与样本

  • 回顾性队列研究,使用大型国家数据库识别接受初次THA的唐氏综合征患者。
  • 共纳入255例唐氏综合征患者(平均年龄43岁,范围9至86岁)。
  • 采用Kaplan-Meier分析评估无翻修THA、无机械失败及无任何后续髋或骨盆手术的生存率。
  • 生成1:1倾向性评分匹配的非唐氏综合征THA队列(每组n=246)比较10年机械结局。

主要发现

  • 10年内翻修THA发生率为4.7%。
  • Kaplan-Meier分析显示10年无翻修生存率94.6%、无机械失败生存率85.9%、无任何后续髋或骨盆手术生存率72.6%。
  • 倾向性评分匹配分析(每组n=246)显示,唐氏综合征与非唐氏综合征患者在翻修THA率(RR 0.92,P=0.84)、机械失败率(RR 1.30,P=0.24)及后续髋或骨盆手术率(RR 1.16,P=0.42)上均无统计学显著差异。

临床怎么用

  • 对于经适当选择的唐氏综合征患者,THA可作为持久的治疗选择。
  • 21三体本身不应被视为THA的禁忌证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients who have Down syndrome (trisomy 21) have unique musculoskeletal and medical characteristics that may influence outcomes after total hip arthroplasty (THA). Although early postoperative complications have been described, 10-year implant survivorship in this population remains poorly defined. This study's objective was to evaluate 10-year implant survivorship and mechanical outcomes following primary THA in patients who had Down syndrome and to compare these outcomes to those of matched patients who did not have Down syndrome. METHODS: A retrospective cohort study was conducted using a large national database to identify patients who had Down syndrome and underwent a primary THA. Longitudinal outcomes were assessed at predefined intervals up to 10 years postoperatively. Kaplan-Meier analyses were used to estimate survivorship free from revision THA, mechanical failure, and any subsequent hip or pelvic surgery. A 1:1 propensity score-matched cohort of patients who did not have Down syndrome undergoing THA was generated to compare 10-year mechanical outcomes. A total of 255 patients who had Down syndrome were included (mean age, 43 years [range, nine to 86]). RESULTS: By 10 years, revision THA occurred in 4.7% of patients. Kaplan-Meier analysis demonstrated a 10-year revision-free survival of 94.6%, a mechanical failure-free survival of 85.9%, and freedom from any subsequent hip or pelvic surgery of 72.6%. In the propensity-matched analysis (n = 246 per group), there were no statistically significant differences between patients who had and did not have Down syndrome in rates of revision THA (risk ratio [RR] 0.92, P = 0.84), mechanical failure (RR 1.30, P = 0.24), or subsequent hip or pelvic surgery (RR 1.16, P = 0.42). CONCLUSIONS: Patients who have Down syndrome undergoing primary THA demonstrate excellent implant survivorship at 10 years comparable to matched controls. Trisomy 21 alone does not appear to compromise 10-year implant durability, supporting THA as a durable treatment option in appropriately selected patients.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Shafau AL, Elnaggar A, Almaat A, et al. Excellent 10-Year Implant Survivorship Following Primary Total Hip Arthroplasty in Patients Who Have Down Syndrome: A Retrospective Cohort Study. J Arthroplasty. 2026. PMID: 42637019. doi:10.1016/j.arth.2026.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。